Purpose

The primary purpose of this Stage 1b NIH-funded clinical trial (K23AG073618, PI Petrovsky) is to determine the efficacy of a 1-month music intervention (Calming Music Personalized for Sleep Enhancement in PeRsons living with Dementia, CoMPoSER) on health outcomes in 72 dyads (144 participants) of persons living with dementia (PLWD) and their caregivers (Stage 1b). The secondary purpose of this research project is to examine the mechanism of stress reduction and sustained effects of the music intervention on PLWD and caregiver well-being. We will evaluate the acceptability of the mobile application CoMPoSER in a pilot RCT and determine the impact of the mobile application CoMPoSER on PLWD (sleep latency, sleep efficiency, wake after sleep onset, total sleep time, sleep quality) and caregiver (perceived stress and well-being) outcomes.

Condition

Eligibility

Eligible Ages
Between 18 Years and 100 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

for persons living with dementia (PLWD): - Age 60 and above - Existing physician diagnosis of dementia or self-reported memory impairment and Clinical Dementia Rating Scale score of greater than 0.5, - Score of >10 on the Insomnia Severity Index - Stable dose of psychotropic medications - Agreeing to wear an actiwatch for the duration of the study PLWD

Exclusion Criteria

  • Hearing impairment - Planned transition to a residential or institutional care facility in 3 months - Presence of extrapyramidal symptoms or acute sleep disruption - Bed bound - Living in an alternative home setting (such as Assisted Living Community) Informal caregivers inclusion criteria: - Age 18 and above. - Providing at least 4 hours of daily care - Living with PLWD - Able to read and communicate in English

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
The study will consist of 144 participants (72 dyads). Dyads will receive 4 weekly phone calls in addition to the baseline and post-intervention in-person home visits. Those receiving the CoMPoSER intervention will undergo the following components: A) relaxation techniques; B) meaningful and relaxing music playlist, tailored to PLWD preferred genre, and C) nighttime routine guidance. Those undergoing the attention control intervention will receive sleep education. The attention control design includes participants finding their own treatment if assigned to no-treatment group and higher study dropout rates.
Primary Purpose
Supportive Care
Masking
Double (Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Sleep Education Group
Participants in this group will receive sleep education.
  • Other: Sleep Education
    Participants in this intervention will receive sleep education based on the NIH/NIA guide, which includes tips for getting a good night's sleep.
Experimental
CoMPoSER Intervention Group
Participants in this group will use a mobile application that plays calming music personalized for sleep enhancement.
  • Other: CoMPoSER intervention group
    Participants in the intervention will use a mobile application that plays calming music personalized for sleep enhancement, relaxation techniques and nighttime routine guidance.

Recruiting Locations

Duke University School of Nursing
Durham, North Carolina 27710
Contact:
Darina Petrovsky
919-681-7041
PetrovskyResearch@duke.edu

More Details

Status
Recruiting
Sponsor
Duke University

Study Contact

Darina Petrovsky
919-684-3786
darina.petrovsky@duke.edu

Detailed Description

Aim 1: Evaluate the acceptability of the mobile application CoMPoSER in a pilot RCT. Aim 2: Determine the impact of the mobile application CoMPoSER on PLWD (sleep latency, sleep efficiency, wake after sleep onset, total sleep time, sleep quality) and caregiver (perceived stress and well-being) outcomes. Aim 3: Examine stress reduction as a mechanism of action measured via salivary cortisol by which 1-month long CoMPoSER intervention affects insomnia symptoms in PLWD. Aim 4: To determine the sustained (3 months) efficacy of CoMPoSER compared to control group on PLWD and caregiver health outcomes.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.